Substituted benzylaminoquinuclidines as substance P antagonists
    6.
    发明授权
    Substituted benzylaminoquinuclidines as substance P antagonists 失效
    取代的苄基氨基奎宁啶作为物质P拮抗剂

    公开(公告)号:US5604241A

    公开(公告)日:1997-02-18

    申请号:US416913

    申请日:1995-04-20

    CPC分类号: C07F9/6561 C07D453/02

    摘要: Compounds useful in the treatment of inflammatory disorders, central nervous system disorders and other disorders of the formula I ##STR1## and the pharmaceutically-acceptable salts thereof, wherein Ar.sup.1 and Ar.sup.2 are each independently aryl or substituted aryl; R.sup.1 is alkyl having from 1 to 6 carbon atoms;R.sup.2 is hydrogen or alkyl having from 1 to 6 carbon atoms;and either X and Y are taken separately and they are each, independently, hydrogen, dialkylphosphoryl having 2 to carbon atoms, alkyl having from 1 to 6 carbon atoms, alkenyl having from 2 to 6 carbon atoms or alkynyl having from 2 to 6 carbon atoms; or X and Y are taken together and they represent a hydrocarbon chain having 3, 4, or 5 carbon atoms, optionally containing up to 2 double bonds and optionally having 1 or 2 substituents selected from oxo, hydroxy and alkyl having from 1 to 6 carbon atoms; or Y is methoxy when X is ethyl; provided that when X and Y are taken together they are attached to adjacent carbon atoms; and provided that if either X or Y is hydrogen, then the other one must be alkenyl or alkynyl; and provided that when Y is methoxy and X is ethyl, then Y is at the 4-position and X is at the 5-position, Ar.sup.1 or Ar.sup.2 must each be phenyl, R.sup.1 is methyl and R.sup.2 is hydrogen.

    摘要翻译: PCT No.PCT / US93 / 09168 Sec。 371日期1995年04月20日 102(e)1995年4月20日PCT PCT 1993年9月30日PCT公布。 公开号WO94 / 08997 日期1994年4月28日可用于治疗炎症性疾病,中枢神经系统疾病和式I的其它病症及其药学上可接受的盐的化合物,其中Ar1和Ar2各自独立地为芳基或取代的芳基; R1是具有1至6个碳原子的烷基; R2是氢或具有1至6个碳原子的烷基; X和Y分开取代,它们各自独立地为氢,具有2-碳原子的二烷基磷酰基,具有1-6个碳原子的烷基,具有2-6个碳原子的链烯基或具有2-6个碳原子的炔基 ; 或X和Y一起并且它们表示具有3,4或5个碳原子的烃链,任选地含有至多2个双键并且任选地具有1或2个选自氧代,羟基和具有1至6个碳原子的烷基的取代基 原子 或当X为乙基时,Y为甲氧基; 条件是当X和Y一起取代时,它们连接到相邻的碳原子上; 并且条件是如果X或Y是氢,则另一个必须是烯基或炔基; 并且条件是当Y为甲氧基且X为乙基时,则Y为4-位,X为5-位,Ar1或Ar2各自为苯基,R1为甲基,R2为氢。

    Method for evaluating drug metabolism and reagent compositions therefor
    7.
    发明授权
    Method for evaluating drug metabolism and reagent compositions therefor 失效
    药物代谢评估方法及其试剂组合物

    公开(公告)号:US5989844A

    公开(公告)日:1999-11-23

    申请号:US132974

    申请日:1998-08-12

    摘要: This invention relates to a method for evaluating the susceptibility of pharmaceutical drugs to metabolism by a specific cytochrome P-450 isozyme, which comprises contacting the sample compound with a reagent composition prepared by adding the specific cytochrome P-450 isozyme to liver microsomes lacking said specific cytochrome P-450 isozyme in a carrier material. More particularly, this invention relates to a useful in vitro quantitative assay for drug metabolism by P-450 isozymes such as CYP2D6, CYP2C19, and CYP2A6. This invention also relates to a reagent composition which is useful for said in vitro assay.

    摘要翻译: 本发明涉及用于评估药物对特定细胞色素P-450同功酶代谢的敏感性的方法,其包括将样品化合物与通过将特异性细胞色素P-450同功酶加入到缺少所述特异性的肝微粒体而制备的试剂组合物 细胞色素P-450同功酶载体材料。 更具体地说,本发明涉及由P-450同功酶如CYP2D6,CYP2C19和CYP2A6进行的药物代谢的有用的体外定量测定。 本发明还涉及可用于所述体外测定的试剂组合物。

    Pyrimido-benzothiazines
    9.
    发明授权
    Pyrimido-benzothiazines 失效
    嘧啶 - 苯并噻嗪

    公开(公告)号:US5418231A

    公开(公告)日:1995-05-23

    申请号:US78315

    申请日:1993-06-28

    IPC分类号: C07D513/04 A61K31/54

    CPC分类号: C07D513/04

    摘要: This invention relates to novel pyrimido-benzothiazine derivative compounds. ##STR1## The compounds of the present invention inhibit the action of the lipoxygenase enzyme and are useful in the treatment or alleviation of inflammatory diseases, allergy and cardiovascular diseases in mammals. This invention also relates to pharmaceutical compositions comprising such compounds.

    摘要翻译: PCT No.PCT / US91 / 09161 Sec。 371日期:1993年6月28日 102(e)日期1993年6月28日PCT 1991年12月16日PCT公布。 公开号WO92 / 12161 本发明涉及新颖的嘧啶 - 苯并噻嗪衍生物化合物。 本发明化合物抑制脂氧合酶的作用,可用于治疗或减轻哺乳动物炎症性疾病,变态反应和心血管疾病。 本发明还涉及包含这些化合物的药物组合物。